Effects of artificial liver treatment frequency and mode on survival time of patients with liver failure

Objective  To explore the effect of the frequency and mode of artificial liver treatment on the prognosis of patients with liver failure.

Methods  A total of 102 patients with liver failure who received artificial liver therapy were selected as the study subjects. The 102 patients were grouped according to the number of artificial liver treatments1 artificial liver treatment group (16 cases), 2 to 4 artificial liver treatment group (69 cases), 5 artificial liver treatment group (10 cases) and ≥6 artificial liver treatment group (7 cases) and the mode of artificial liver treatment groupplasma exchange (PE group, 69 cases), dual plasma molecular adsorption system group (DPMAS group, 2 cases) and combination group (31 cases). M-W or K-W nonparametric tests were used for assay indexes among each group, K-M survival analysis was used for comparison of survival time of each component, and Log-rank tests were conducted in parallel.

Results  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the 1 artificial liver treatment group were significantly higher than those in other groups, and the improvement of albumin (ALB) in the 2 to 4 artificial liver treatment group was significantly lower than that in the other groups, the improvement of prothrombin time activity (PTA) in the artificial liver treatment group after 1 time, 2 to 4 times was significantly lower than that in the other two groups (P < 0.05). The 24-week survival rate was the highest in the group receiving 5 times of artificial liver treatment, and the lowest in the group receiving ≥6 times of artificial liver treatment. Before treatment, PTA was significantly lower in the PE group than the combined group (P < 0.05); there was no significant difference in survival rate among different artificial liver treatment modes (P>0.05). The 24-week survival rate was the highest in patients aged 14 to 45 years and the lowest in patients aged 46 to 54 years.

Conclusion  There is no significant difference in survival rate of patients with liver failure in different artificial liver treatment modes. The survival rate of patients receiving multiple artificial liver therapy is higher than that of patients receiving single therapy, and the survival time of patients is prolonged with the increase of the number of treatments, but the survival rate of patients receiving more than 6 treatments is decreased.